SEC Form 4 · accession 0000899243-18-023153
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bryan M. Reasons
Officer — CFO
Period of report
Aug 21, 2018
Accepted (ET)
Aug 23, 2018 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001723128
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Aug 21, 2018 | S | 11,698 | $23.65 | D | 82,986 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.55 to $23.78. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.